Format

Send to

Choose Destination
Pharmacogenomics J. 2016 Aug;16(4):393-8. doi: 10.1038/tpj.2015.57. Epub 2015 Aug 11.

Attitudes of clinicians following large-scale pharmacogenomics implementation.

Author information

1
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
2
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
3
Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.
4
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
5
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
6
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
7
Centers for Disease Control and Prevention, Atlanta, GA, USA.
8
University of Texas Medical Branch, Galveston, TX, USA.
9
Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
10
Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, TN, USA.

Abstract

Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients' response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug-genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.

PMID:
26261062
PMCID:
PMC4751074
DOI:
10.1038/tpj.2015.57
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center